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Abstract
Background: To determine whether training community health workers (CHWs) about hypertension in order to
improve adherence to medications is a cost-effective intervention among community members in South Africa.
Methods: We used an established Markov model with age-varying probabilities of cardiovascular disease (CVD)
events to assess the benefits and costs of using CHW home visits to increase hypertension adherence for individuals
with hypertension and aged 25–74 in South Africa. Subjects considered for CHW intervention were those with a
previous diagnosis of hypertension and on medications but who had not achieved control of their blood pressure.
We report our results in incremental cost-effectiveness ratios (ICERs) in US dollars per disability-adjusted life-year
(DALY) averted.
Results: The annual cost of the CHW intervention is about $8 per patient. This would lead to over a 2% reduction
in CVD events over a life-time and decrease DALY burden. Due to reductions in non-fatal CVD events, lifetime costs
are only $6.56 per patient. The CHW intervention leads to an incremental cost-effectiveness ratio of $320/DALY
averted. At an annual cost of $6.50 or if the blood pressure reduction is 5 mmHg or greater per patient the
intervention is cost-saving.
Conclusions: Additional training for CHWs on hypertension management could be a cost-effective strategy for CVD in
South Africa and a very good purchase according to World Health Organization (WHO) standards. The intervention
could also lead to reduced visits at the health centres freeing up more time for new patients or reducing the burden
of an overworked staff at many facilities.
Keywords: Community health workers, Hypertension, Cost-effectiveness
Background
The burden of non-communicable diseases (NCDs) in low
and middle income countries (LMIC) is very high and
compounds the effects of the already high burden of infec-
tious diseases [1]. Of the NCDs, hypertension is a major
burden in general and in particular in South Africa with
trends showing a growth of 20% for both men and women
over the past decade [2]. Of further significance is that
adherence to hypertension medication varies significantly
from under 10% in the lowest socio-economic status
(SES) quintile compared to 80% in the highest quintile [3].
Furthermore, HIV/AIDS can now be regarded as a treat-
able chronic illness, with the expectation that persons with
HIV/AIDS will live longer and lead more active lives. This
will increase their exposure to CVD risk including hyper-
tension [4].
However, effective management of patients who are at
high risk for NCDs in low-resource settings is challenging
due to limited human and financial resources [5]. In
response, the South African Department of Health has
recently acknowledged the need for improved community
based care for NCDs and is currently undergoing a major
‘re-engineering’ of its Primary Health Care (PHC) system
[6]. The goal of the restructuring is to ensure the service
capacity necessary to manage the ongoing infectious dis-
ease challenges in addition to the rising demands from
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numbers of doctors and nurses. The restructuring of the
PHC will include the training of over 50,000 Community
Health Workers (CHWs.) In addition to the traditional
training for maternal and child health, HIV/AIDS, and
tuberculosis, authorities have considered that training in
Cardiovascular Disease management is necessary.
It is thus worthwhile to consider which lessons from
prior initiatives with CHWs may be applicable to Cardio-
vascular Disease interventions. Currently, the utilization
of CHWs in many low and middle income countries tends
to focus on infectious disease management. Where CHWs
have been used to manage NCDs, this has largely been for
improving adherence and lifestyle choices, or screening
for cancer. Finally, the WHO has also articulated the
explicit recommendation for the existence of referral sys-
tems as part of managing care and for the appropriate
training of health workers to use them [7]. However, to
date, there is no evaluation of the cost-effectiveness of
CHWs in aiding adherence to medications for cardiovas-
cular disease (CVD).
We therefore propose to evaluate the cost-effective-
ness of training CHWs to help with the adherence of
stabilized hypertensive patients within the PHC system.
If effective, this would serve two purposes. First, patients
with the diagnosis of hypertension may benefit from im-
proved control of their hypertension. Second, the staff at
primary care facilities will be able to manage newly diag-
nosed conditions and not be overwhelmed, as patients
are cared for in the community rather than depending
on frequent PHC visits.
Methods
Strategies compared
We used a previously established Markov model with
age-varying probabilities of CVD events to assess the
benefits, risks, and costs of a program to increase hyper-
tension adherence for individuals aged 25–74 in South
Africa. In South Africa, under standard care 42% of the
population is aware of their diagnosis, with only about
15% having their blood pressure controlled [8]. We eva-
luated the benefit of having CHWs visit patients with
uncontrolled hypertension two times a year. This stra-
tegy was compared to usual care and control rates.
Model description
In order to evaluate the full benefits and costs of the in-
creased screening, we used Markov modeling with age-
varying probabilities of cardiovascular disease events and
mortality. The model has been described in detail else-
where [9,10] but we describe it briefly here. The popula-
tion distribution for adults between the ages of 25–74, by
age and sex, was taken from the South African census
data. The country-specific distributions of blood pressure
and smoking rates, was taken from the South African
demographic and health surveys of 1998 and 2003
updates [8,11]. Cholesterol values, by age and sex, were
taken from the Global Burden of Disease project [12,13].
Diabetes distributions by age and sex were obtained from
the Global Burden of disease with updates from the South
African Medical Research Council study on the burden of
diabetes [14].
Each year the cohort in each country faces a proba-
bility of death from a non-cardiac cause, developing cor-
onary heart disease, having a stroke, or surviving free of
CVD. The annual probability of non-cardiac death is
based on life tables provided by the WHO for South
Africa [15]. The risks for a first event if untreated—
either coronary heart disease (CHD) or stroke—were
based on separate Framingham risk functions for each
event [16,17]. In the initial 35 days following an MI or
stroke, individuals face various probabilities of surviving,
having a repeat MI, dying from the MI, or having a
bleeding complication or repeat stroke. After 35 days,
survivors face separate probabilities of dying in the first
year and in subsequent years based on age, and of ha-
ving a debilitating stroke. Mortality and event proba-
bilities for the first 35 days, the first year, and the
following years for the group without secondary treat-
ment were taken from the control cohort of the ISIS-2
[18] trial. Repeat events and subsequent CHD and stroke
events were tracked for each individual, and affected
mortality, quality-of-life, and costs, accordingly.
At the end of each year, the cohort is then redistri-
buted to one of five health states. The five states are
“disease-free” (no CVD event or death from other causes),
“post-myocardial infarction (MI)”, “angina”, “post-cerebro-
vascular accident (CVA)”,a n d“dead”.F o rt h o s ei nt h e
disease-free state, the risk factors update with age, which
updates annually. All analyses were performed using Tree-
Age Pro Suite 2009 by TreeAge Software Incorporated
(Williamstown, Massachusetts). Table 1 lists the model in-
put parameters for disease progression.
Effectiveness data
We rely on the only two studies using CHWs in the com-
munity for blood pressure control for the effect of the
intervention- one in inner city Baltimore [39] and one in
rural Taiwan [40]. Both observed a significant reduction in
systolic blood pressure. The first, a randomized control
trial of home visits for blood pressure management, ob-
served a 3–6 mm reduction in blood pressure over
3.5 years, an effect which disappeared after home visits
ceased. No difference was observed between those in the
standard intervention group (one visit) and those in the
more intensive intervention group (5 additional visits). In
Taiwan, measurements taken in one city before and after a
CHW intervention for blood pressure management found
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then applied the average blood pressure reduction from a
meta-analysis of the trials [41] using these levels of treat-
ment with an average of 22% reduction in coronary heart
disease events and a 41% reduction in stroke per 10 mmHg
reduction in systolic blood pressure. Table 2 describes the
necessary inputs for this intervention.
Intervention description
We evaluated a simulation intervention where six CHWs,
over a 2-day period, will be trained, to measure blood
pressure using an automated blood pressure cuff, and
about the etiology and prevention of hypertension and
cardiovascular disease. Following training, each CHW
would be given a list of hypertensive patients registered at
a nearby clinic, with their home address. We estimate that
each CHW could feasibly make 6 home visits per day
based on a population density of approximately 2500
adults/5 km
2, of which roughly 21% are hypertensive [8].
In rural areas we estimate up to four visits and in deep
rural areas up to 3 visits a day due to the distances bet-
ween households. Each CHW will be responsible for visi-
ting each of their patients twice per year (approx. 245
working days) in order to monitor their blood pressure
and treatment adherence, teach about healthy lifestyle
choices and encourage follow-up visits with a doctor if ne-
cessary (which might require visiting the nearest district
hospital). Both the CHW and the patient would record
Table 1 Disease progression inputs used in the CVD
micro-simulation model
Parameter Value Source
From disease
free state
Non-CVD death Age- and sex-
specific table
NCHS [19]
Stroke event RF-based
equation
Wolf [17]
CHD event RF-based
equation
Anderson [20]
% Cardiac arrest Age- and sex-
specific table
Weinstein [21]
% MI (males) 0.350 NHLBI [22], ARIC [23]
% MI (females) 0.200 NHLBI [22], ARIC [23]
% Angina Formula 100% -% Cardiac
arrest -% MI
From cardiac arrest state
Acute (within 1 year) death 0.954 Nichol [24]
Chronic (post 1
st-year) death 0.040 Assumption: same as MI
From MI state
Acute death Age- specific
table
McGovern [25], Roger [26],
Lee [27]
Acute CABG 0.082 Fang [28]
Acute PTCA 0.300 Fang [28]
% Procedure death 0.009 Dorros [29]
Acute 2
nd MI (after PTCA) 0.052 BARI [30]
Chronic (post 1
st-year) death 0.040 Law [31]
>1 previous MI 0.100 Law [31]
Repeat MI 0.064 Jokhadar [32]
From MI and CABG state
Acute post-CABG death 0.027 Peterson [33]
Acute 2
nd MI 0.051 BARI [30]
Chronic (post 1
st-year) death 0.040 Assumption: same as MI
>1 previous MI 0.100 Assumption: same as MI
Repeat MI 0.039 Yusuf [34], Jokhadar [32]
From angina state
Acute death 0.045 Capewell [35]
Acute cardiac arrest 0.006 Hsia [36]
Acute MI 0.035 Hemingway [37]
Acute CABG 0.200 Ford [38]
Acute PTCA 0.300 Ford [38]
Chronic (post 1
st-year) death 0.030 Law [31]
Chronic (post 1
st-year) MI 0.035 Hemingway [37]
Table 1 Disease progression inputs used in the CVD
micro-simulation model (Continued)
From angina and
CABG state
Chronic (post 1
st-year)
death
0.018 Yusuf [34], Law [31]
Chronic (post 1
st-year) MI 0.021 Yusuf [34],
Hemingway [37]
Table 2 Intervention parameters applied to South Africa
Parameter Value
Number of visits by CHW per
hypertensive patient
2 per year
Reduction in blood pressure 4 mmHg (2–7 mmHg)
Number of households per CHW
Average 260
Urban 300
Rural 225
Deep rural 150
Number of CHWs per Nurse coordinator 6
Number of training days/year 2
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tor any changes. The CHW will report weekly to the Pro-
gram Coordinator (usually a nurse supervisor) who will be
responsible for supervising the work of up to 30 CHWs.
Outcome measures and costs
Costs for the various inputs of the intervention including,
CHW salaries, a nurse supervisor per five CHWs, and the
training costs are listed in Table 3. The main goal of this
hypertension adherence and education program is to
prevent more serious sequelae of myocardial infarction,
angina, and stroke. Potential cost savings of disease man-
agement of these acute CVD events and chronic care are
listed in Table 4. Costs for treatment of myocardial in-
farction and stroke are based on an ingredients based
approach where we calculate average number of hospital
days per each event; physician, nurse, and hospital per-
sonnel costs; medication use, and laboratory testing. Input
costs are taking from the WHO CHOICE (CHOosing In-
terventions that are Cost Effective) costs estimates. Costs
were reported in $US for 2012.
Outcomes in the analyses were measured in quality ad-
justed life-years gained and net health-care costs. Total life
years and DALYs were accumulated for the population for
both the standard of care currently in place and the CHW
intervention. DALYs were obtained by use the weighted
disease-state values from the Disability Weights of the
WHO Global Burden of Disease project and are listed in
Table 4.
Statistical analysis
Incremental cost-effectiveness ratios were calculated as
the difference in costs between competing strategies di-
vided by the increase in DALYs averted. To compare one
strategy with the next more expensive alternative, we used
incremental cost-effectiveness ratio (ICER), which is the
difference in costs divided by the difference in DALYs.
Sensitivity analyses on the effectiveness of the intervention
relied on the upper and lower limits of the expected bene-
fits from increased adherence. Specifically, we assessed the
range of estimates on the number of visits depending on
population density and the responsiveness to the remin-
ders about medications and changes to the lifestyle advice
received. Furthermore, we evaluated the absolute costs
and reductions at increasing proportions of those respon-
sive to the CHW program. Sensitivity analyses were con-
ducted on the range of costs presented for CHW salary,
the number of visits per year, the mortality from myocar-
dial infarction, and costs of hospitalization. Given uncer-
tainty around the predictive accuracy of the Framingham
Risk Function outside of the United States [42] we tested
whether the risk over or understanding ischemic heart dis-
ease in South Africa would have an impact on the results.
Table 3 Intervention specific costs, South Africa
Unit cost in $US
Salary
Community Health Worker (CHW)
annual salary
3750 (3187.5 – 4312.5)
Program coordinator annual salary 27933 (23743.05 – 32122.95)
Training
Trainer daily salary 116.3875 (98.93 – 133.85)
CHW per diem 32.5 (27.63 – 37.38)
Trainer per diem 32.5 (27.63 – 37.38)
Room rental per day 31.25 (26.56 – 35.94)
Chairs 12 (10.20 – 13.80)
Desks 2.8625 (2.43 – 3.29)
Laptop computer 525 (446.25 – 603.75)
Projector 125 (106.25 – 143.75)
Projector screen 125 (106.25 – 143.75)
Notebook 0.125 (0.11 – 0.14)
Pencil 0.00875 (0.0074 – 0.010)
Home visits and follow-up
Cell phone and minutes 15 (12.75 – 17.25)
Automated blood pressure cuff 87.5 (74.38 – 100.63)
Recording sheet for patient 0.04 (0.034 – 0.046)
Educational pamphlets 0.375 (0.32 – 0.43)
Table 4 Cost and utilities related to cardiovascular
disease events in the model
Parameter Base-case
value
Sensitivity analysis
value(s)
Acute costs for disease states
MI $1112 +/−15%
Stroke $1564 +/−15%
Chronic annual costs for
secondary prevention
All CHD states $300 +/−15%
Stroke $900 +/−15%
Blood pressure treatment costs
Annual treatment $28.87-88.03 +/−15%
Annual lab costs $6 +/−15%
Disutilities for disease states
Acute MI 0.439 0.405-477
Angina 0.124 0.105-0.141
Acute stroke 0.92 +/−15%
Post stroke 0.266 0.228-0.295
Disutilities for repeat event
Repeat MI event −0.049 +/−15%
Repeat stroke event −0.052 +/−15%
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the key variables of the model listed in the tables.
Results
The cost of the intervention, including training, of
CHWs visiting the household of a hypertensive patient
two times per year is about $8 per patient per year.
However, the costs are somewhat offset by reductions in
2% of non-fatal cardiovascular disease events over a life-
time. As a result of these offsets, the net annual cost is
less than $0.50 per person with only an additional life-
time cost of $6.56 per patient. Table 5 lists the life time
costs, effects, and incremental cost-effectiveness ratio for
the intervention and the current standard. The CHW
intervention leads to an incremental cost-effectiveness
ratio of $320/DALY averted. This is well below a willing-
ness to pay threshold of $2154 (Afro E region of WHO)
or $10,000 (South Africa GDP per capita) for a “very
good buy” set by the WHO’s CHOICE program.
The cost-effectiveness of the intervention is somewhat
sensitive to the cost of the intervention. One of the
largest drivers of variation in costs was the number of
households that could be visited by CHWs in regions of
differing population density (Table 6). In urban areas the
cost-effectiveness of the intervention was $17/DALY
averted, compared with the ratio of $1529/DALY averted
in deep rural areas where the number of visits per day
were estimated to be half of that in an urban area. The
cost-effectiveness of the intervention in widely spread
‘average’ rural areas lies between the two at about $772/
DALY averted, which is about twice the national average.
When we tested the sensitivity of the CHW intervention
to the cost per patient, the intervention remained cost
effective (Figure 1). Above our base case annual cost of $8
per patient the intervention remained cost-effective even
with a near doubling of the cost at $15 per patient ($1900/
DALY). Once the annual cost per patient was below $6.50,
the CHW intervention became “cost-saving” (i.e. it both
saved costs and increased life-expectancy). The results
were also favorable across the full range of estimates of
the benefit of the intervention on blood pressure reduc-
tion (Figure 2). At the levels below the base case assump-
tion of 4 mmHg the intervention remained cost-effective
down to a level of only 2 mmHg reduction where it was
just under $2000/DALY averted. Once the blood pressure
reduction was above 4.98 mmHg, the CHW intervention
became cost-saving. Results were not sensitive to changes
in the cost of hospitalizations or CHW salary; that is, the
ICERs remained below $2000/DALYaverted.
The results were not sensitive to a change in the mor-
tality rate from myocardial infarction of 50% more or
less than the baseline rate assumed in the model (ICERs
for the CHW intervention compared to the standard of
care ranged from ($305-$335/DALY averted. The results
were also not sensitive to a cost of an MI ranging 50%
above and below the base case value (range of ICERs
$316-$326/DALY averted). When we assessed the pre-
dictive accuracy of the Framingham risk score, we found
the results were somewhat sensitive to whether it over
or underestimates risk in South Africans but all results
remained well under the willingness to pay of $10,000
per DALY averted. If the risk score overestimates by up
to 50% relatively an individual’s risk the ICER for the
CHW intervention increases to $2991/DALY averted.
If it underestimates the risk by 50%, the ICER for the
CHW intervention becomes cost-saving, that is saves
lives and costs less than the standard of care.
The results of the probabilistic sensitivity analysis
(Figure 3) showed the results to be quite robust. The mean
ICER was $223/DALY with 95% of the results remaining
in an interval ranging from $0.40-$402/DALY averted.
The maximum ICER comparing the CHW intervention to
the standard of care was $441/DALY averted. The mini-
mum values showed that the CHW intervention was cost-
saving.
Discussion
Our analyses have shown that an intervention of training
CHWs to educate patients about the risk of hypertension
and the benefits of life-style changes and adherence to
medications would lead to cost-effective prevention of car-
diovascular diseases at about $320/DALY averted. Even
with a conservative estimate of a 2 mmHg reduction in
systolic blood pressure, or almost a doubling of the cost of
the intervention, the incremental cost-effectiveness ratio
(ICER) remains below $2000/DALYaverted. The interven-
tion would lead to approximately 2% reduction in strokes
and a 1% reduction in ischemic heart disease. Overall
these estimates likely underestimate the benefit of the
intervention as we did not include reductions in conges-
tive heart failure and end-stage renal disease that are also
affected by increased blood pressure. Another under-
estimation of the benefits includes the fact that when
CHWs who encourage the adherence to one medication
Table 5 Cost, effects, and cost-effectiveness: CHW intervention against hypertension, South Africa
Strategy Cost Incremental cost ($US) DALY Incremental DALY averted C/E ($/DALY) ICER
Standard 2133.03 14.0508 151.81
CHW 2139.59 6.56 14.0713 0.0205 152.05 320
DALY = Disability Adjusted Life Year; C/E = Cost-effectiveness; ICER= Incremental Cost-effectiveness ratio.
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chronic conditions such as dyslipidemia and diabetes and
thus could further reduce CVD and other chronic condi-
tions. An emphasis on overall CVD risk has been shown
to be more cost-effective [43] than just focusing on blood
pressure and we ultimately suggest that CHW training on
multiple CVD risk factors together may have a greater
impact.
The WHO considers interventions to be cost-effective
if they fall below three times gross-national income per
capita. The ICERs we report in the main analysis and
across the range of sensitivity analyses all fell below this
threshold for South Africa as well as for most of the
sub-Saharan African countries. Out main finding would
be a “very good buy” according to WHO CHOICE cri-
teria of less than one times gross national income (GNI)
per capita in South Africa and neighboring countries.
These values make this strategy a likely good option for
many African and potentially other low and middle in-
come countries.
Overall, there is a paucity of reported research on CHWs
for CVD in developing countries; however, there is ample
information about their use for infectious disease inter-
ventions in these settings. Several studies in developing
countries have identified elements that are essential to the
success of CHW interventions, such as community in-
volvement in selecting CHWs, integration with existing
health systems, adequate and ongoing training, and proper
supervision [44,45]. Monetary payment for CHW services
are useful and increasingly favored [46], though non-
monetary incentives also help to reduce turnover [47].
These findings, which are similar to those from a review of
CHWs in the United States [48], are likely to apply to
CHW interventions for NCDs as well. Even a doubling of
the CHW salary that we used would make this an attrac-
tive intervention.
Our study adds to the limited data available on the cost-
effectiveness of task-shifting. Task-shifting from physicians
to nurses in managing NCDs such as hypertension has
been shown to be effective in several countries [49]. A
review of the evidence regarding nurse-led interventions
reveals that nurses are effective at the management of dia-
betes in primary care, outpatient, and community settings
[50]; and in reducing hospitalizations, days spent in hos-
pital, multiple readmissions, patient care, and cost-savings,
even after factoring in the cost of the intervention [51].
One study in Pakistan [52] suggested that in addition to
the education by community members, the general practi-
tioners (GPs) taking care of the patients also had to have
an adequate understanding of managing hypertension. In
this study, GPs plus community education led to up to
10 mmHg reductions in blood pressure. While we believe
the training in South Africa for hypertension management
among doctors is adequate, nurse training in chronic dis-
eases in many regions remains deficient. Still, the lack of
human resources in LMICs overall, negatively impacts the
ability of nurses to manage NCDs and the deployment of
Table 6 CHW vs standard intervention – by population
density
Population density Incr C/E (ICER)
Urban 17
Rural 772
Deep rural 1,529
ICER = Incremental cost-effectiveness ratio.
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Figure 1 Effect of CHW intervention cost on incremental cost-effectiveness ratios (ICERs)*. Red line below zero results in a negative ICER
which means that the CHW intervention is cost-saving.
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On average a hypertensive patient visits the primary health
center 12 times a year to pick up medications and sees his
or her nurse or physician 3–4 times per year. If the CHW
visits can cut out 1–2 of these provider visits, then nurses
would be freed up to either take on newly diagnosed
patients with NCDs or better manage the already chal-
lenging case-load.
Another question is whether the CHWs can manage
the workload. There are approximately 7.5 million South
Africans with hypertension according to the 2003 WHO
definition [53]. With only 42% aware of their diagnosis
and only 15% controlled, there remain approximately 2.5
million who could benefit from improved hypertension
management in the public sector that are already iden-
tified. Upwards of 50,000 CHWs are anticipated to be
trained over the long term with the roll-out of primary
health care re-engineering in South Africa. In this sce-
nario, at capacity, each CHW takes responsibility for ap-
proximately 50 patients with hypertension. This is about
one per 6 households that are expected to be managed
by the CHW. The CHW could devote two of her ex-
pected 15–30 household visits per week (depending
whether deep rural or urban) and comfortably accom-
plish this goal. Further, other care can be provided in
this visit to increase economies of scale such as re-
minders about medications for other chronic conditions.
In addition it appears that the intervention would even
be cost-effective in remote areas where visits per CHW
may be more challenging to achieve due to geography
and population density.
The study has several limitations. First, the benefits of
the intervention are based on studies outside of South
Africa where, we used estimates from both a US study
and one based in Taiwan. Other studies though have
shown that task-shifting lead to improved treatment ad-
herence for HIV medications and for mental health in
South Africa and may be cost-effective [54-56]. A 20%
increase in adherence may lead to a 4 mmHg blood
pressure reduction [57,58]. Additional gains with lifestyle
advice and visit reminders could lead to further reduc-
tions. A second limitation is the use of WHO CHOICE
results for event cost estimates. Until such local South
African data can be procured through additional studies,
we are reliant on WHO provided estimates. However,
our cost estimates are quite conservative and any in-
crease in the cost of CVD events would lead to more
favorable cost –effectiveness ratios. Furthermore, the
ICERs were quite robust even when a doubling of the
cost of the intervention was assessed. A third limitation
is our assumption that the benefit would be the same for
all patients. However, there may be differences in re-
sponsiveness to the intervention based on geographic
location, level of prior experience with CHWs in certain
areas of South Africa (primarily urban), or income of the
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Figure 2 Effect of estimated BP reduction from intervention on
incremental cost-effectiveness ratios (ICERs)*. *Red line below
zero results in a negative ICER which means that the CHW intervention
is cost-saving.
Figure 3 Probabilistic sensitivity analysis-distribution of incremental cost-effectiveness ratios*. *Negative ICER values reflect that the CHW
intervention is cost-saving compared to the standard of care.
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ferences exist. One of the key conclusions is that this
CHW intervention addressing both adherence and iden-
tification has the potential to be especially important for
the lowest quintiles of the population, many of whom
live in the rural and deep rural areas of South Africa.
Conclusion
This study found that CHWs could potentially have a sig-
nificant impact on chronic conditions in South Africa and
other middle-income countries leading to improved blood
pressure control and reduced strokes and myocardial in-
farctions. The demands on CHWs in South Africa and
elsewhere are going to continue to grow as the health
transition unfolds and CVD burden grows while health
care professional numbers continue to be less than ad-
equate for the need. Questions regarding how best CHWs
can contribute to the overall care and education of
the public will remain. However, it appears that training
CHWs to improve community knowledge and individual
adherence to medications for hypertension (and poten-
tially other chronic non-communicable conditions) may
be one valuable use of scarce human resources for one of
the leading causes of death and disability in South African
adults.
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